Membrane-based therapeutic plasma exchange: Proposed techniques for preventing filter failure.

calculated filtration fraction filter failure heparin plasma volume pre-filter saline dilution trans-membrane pressure

Journal

Journal of clinical apheresis
ISSN: 1098-1101
Titre abrégé: J Clin Apher
Pays: United States
ID NLM: 8216305

Informations de publication

Date de publication:
Oct 2023
Historique:
revised: 19 05 2023
received: 04 03 2023
accepted: 23 05 2023
medline: 23 10 2023
pubmed: 8 6 2023
entrez: 8 6 2023
Statut: ppublish

Résumé

Therapeutic plasma exchange (TPE) is commonly performed using membrane-based TPE (mTPE) and is prone to filter failure. We report on 46 patients, with a total of 321 mTPE treatments using the NxStage machine. This was a retrospective study with an aim to evaluate the effect of heparin, pre-filter saline dilution and the impact of total plasma volume exchanged (< 3 L vs. ≥3 L) on the rate of filter failure. Primary outcome was the overall rate of filter failure. Secondary outcomes included factors that may have indirectly influenced the rate of filter failure, including hematocrit, platelet count, replacement fluid (Fresh Frozen Plasma vs. albumin), and access type. We found that treatments that received both pre-filter heparin and saline had a statistically significant decrease in filter failure rate as compared to those that received neither (28.6% vs. 5.3%, P = .001), and compared to the treatments that received pre-filter heparin alone (14.2% vs. 5.3%, P = .015). In treatments that received both pre-filter heparin and saline predilution, we noted a significantly higher filter failure rate when the plasma volume exchanged was ≥3 L as compared to those that had <3 L exchanged (12.2% vs. 0.9%, P = .001). Rate of filter failure in mTPE can be reduced by implementing several therapeutic interventions including pre-filter heparin and pre-filter saline solution. These interventions were not associated with any clinically significant adverse events. Despite the above-mentioned interventions, large plasma volume exchanges of ≥3 L can negatively impact filter life.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
Therapeutic plasma exchange (TPE) is commonly performed using membrane-based TPE (mTPE) and is prone to filter failure.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS METHODS
We report on 46 patients, with a total of 321 mTPE treatments using the NxStage machine. This was a retrospective study with an aim to evaluate the effect of heparin, pre-filter saline dilution and the impact of total plasma volume exchanged (< 3 L vs. ≥3 L) on the rate of filter failure. Primary outcome was the overall rate of filter failure. Secondary outcomes included factors that may have indirectly influenced the rate of filter failure, including hematocrit, platelet count, replacement fluid (Fresh Frozen Plasma vs. albumin), and access type.
RESULTS RESULTS
We found that treatments that received both pre-filter heparin and saline had a statistically significant decrease in filter failure rate as compared to those that received neither (28.6% vs. 5.3%, P = .001), and compared to the treatments that received pre-filter heparin alone (14.2% vs. 5.3%, P = .015). In treatments that received both pre-filter heparin and saline predilution, we noted a significantly higher filter failure rate when the plasma volume exchanged was ≥3 L as compared to those that had <3 L exchanged (12.2% vs. 0.9%, P = .001).
CONCLUSIONS CONCLUSIONS
Rate of filter failure in mTPE can be reduced by implementing several therapeutic interventions including pre-filter heparin and pre-filter saline solution. These interventions were not associated with any clinically significant adverse events. Despite the above-mentioned interventions, large plasma volume exchanges of ≥3 L can negatively impact filter life.

Identifiants

pubmed: 37287385
doi: 10.1002/jca.22065
doi:

Substances chimiques

Heparin 9005-49-6
Saline Solution 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

555-561

Informations de copyright

© 2023 Wiley Periodicals LLC.

Références

Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis. 2008;52(6):1180-1196.
Ahmed S, Kaplan A. Therapeutic plasma exchange using membrane plasma separation. Clin J Am SocNephrol. 2020;15(9):1364-1370.
Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian apheresis study group. N Engl J Med. 1991;325(6):393-397.
Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. Br Med J (Clin Res ed). 1985;291(6510):1671-1673.
Henderson LW. Pre vs. post dilution hemofiltration. Clin Nephrol. 1979;11(2):120-124.
Kaplan AA, Longnecker RE, Folkert VW. Continuous arteriovenous hemofiltration. A report of six months' experience. Ann Intern Med. 1984;100(3):358-367.
Kaplan AA. Predilution versus postdilution for continuous arteriovenous hemofiltration. Trans Am Soc Artif Intern Organs. 1985;31:28-32.
Kaplan AA. Clinical trials with predilution and vacuum suction: enhancing the efficiency of the CAVH treatment. ASAIO Trans. 1986;32(1):49-51.
Cabral P, Kaplan AA, Phachu D, Shah M, Attique HB, Elali I. Impact of prefilter dilution on IgG removal in membrane-based therapeutic plasma exchange. Ther Apher Dial. 2022;26(4):836-839.
Gashti CN, Andreoli DC, Patel D. Membrane-based therapeutic plasma exchange (mTPE): technical and clinical experience. J Clin Apher. 2018;33(1):38-45.
Elali I, Delasos L, Phachu D, Shah M, Mu J, Kaplan AA. Membrane-based therapeutic plasma exchange: hemodynamics and operational characteristics leading to procedure failure. J Clin Apher. 2021;36(6):841-848.
Hester JP, Ayyar R. Anticoagulation and electrolytes. J Clin Apher. 1984;2(1):41-51.
Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131(4):417-430.

Auteurs

Ibrahim Elali (I)

UConn Health, Department of Medicine, Division of Nephrology, University of Connecticut School of Medicine, Farmington, Connecticut, USA.

Deep Phachu (D)

UConn Health, Department of Medicine, Division of Nephrology, University of Connecticut School of Medicine, Farmington, Connecticut, USA.

Nick Coombs (N)

UConn Health, Department of Medicine, Division of Nephrology, University of Connecticut School of Medicine, Farmington, Connecticut, USA.

Mamta Shah (M)

UConn Health, Department of Medicine, Division of Nephrology, University of Connecticut School of Medicine, Farmington, Connecticut, USA.

Jordan Dean (J)

Division of Nephrology/Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut, USA.

Lalarukh Haider (L)

UConn Health, Department of Medicine, Division of Nephrology, University of Connecticut School of Medicine, Farmington, Connecticut, USA.

Yanlin Wang (Y)

Division of Nephrology/Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut, USA.

Andre A Kaplan (AA)

Division of Nephrology/Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH